Strides Arcolab, Cadila Healthcare, Ranbaxy, Sequent Scientific and Cipla will remain in focus as Gilead Sciences Inc has granted licence to these firms to sell a Hepatitis C drug in developing countries. The tie-ups will allow them to make and sell copies of the drug at lower prices in developing countries. The firms will set their own prices, paying a royalty to Gilead. Analysts will be tracking the development as there are about one crore patients suffering from Hepatitis C in India.

Rights issue buzz on GMR Infra, Usha Martin

Shares of GMR Infrastructure and Usha Martin will be tracked keenly by marketmen as these company boards meet on Tuesday to consider a rights issue. The infrastructure developer, which has interests in airports, energy and highways, did not specify the amount it was looking to raise. GMR recently had raised ₹1,478 crore through an institutional placement. The board of Usha Martin will discuss various fund-raising options, including rights issue. Size and pricing will be keenly watched.

Shilpi Cable Tech turns ex-bonus

Shares of Shilpi Cable Technologies will remain in focus as the stock turns ex-bonus on Tuesday. It has announced a 1:1 bonus and has fixed the record date as September 17. Ex-bonus date is the date from which the stock begins to trade without the bonus shares. In other words, those who buy the stock from September 15 will not be eligible to receive the bonus shares. The company had reported a net profit of ₹8.9 crore for the quarter ended June 2014 and ₹28 crore for FY14.

Related Topics
comment COMMENT NOW